Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 7, Issue 3
February 14 2023
Issue Cover

Table of Contents

STIMULUS REPORTS

Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance
Dearbhla Doherty,Michelle Lavin,Mary Byrne,Margaret Nolan,Jamie M. O’Sullivan,Kevin Ryan,Niamh M. O’Connell,Sandra L. Haberichter,Pamela A. Christopherson,Jorge Di Paola,Paula D. James,James S. O’Donnell,on behalf of the Zimmerman Program Investigators
View Articletitled, Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance
Supplemental data
Absolute neutrophil count by Duffy status among healthy Black and African American adults
Clinical Trials & Observations
Lauren E. Merz,Charlotte M. Story,Miriam A. Osei,Katherine Jolley,Siyang Ren,Hae Soo Park,Revital Yefidoff Freedman,Donna Neuberg,Robin Smeland-Wagman,Richard M. Kaufman,Maureen O. Achebe
View Articletitled, Absolute neutrophil count by Duffy status among healthy Black and African American adults
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
Clinical Trials & Observations
Misha C. Tran,Yasmin Hasan,Amy Wang,Kamil Yenice,Julien Partouche,Wendy Stock,Richard A. Larson,Satyajit Kosuri,James L. LaBelle,Justin Kline,Peter A. Riedell,Andrew S. Artz,Ralph Weichselbaum,Michael R. Bishop,Bulent Aydogan,Hongtao Liu
View Articletitled, A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
Supplemental data
A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia
Clinical Trials & Observations
John Grainger,James Bussel,Michael Tarantino,Nichola Cooper,Donald Beam,Jenny Despotovic,Alexey Maschan,Kejia Wang,Melissa Eisen,Charles Bowers
View Articletitled, A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia
Supplemental data
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
Clinical Trials & Observations
Charles T. Quinn,Richard T. Wiedmann,Daniel Jarovsky,Eduardo Lopez-Medina,Hilze M. Rodriguez,Melanie Papa,Gordana Boggio,Qiong Shou,Ron Dagan,Peter Richmond,Kristen Feemster,Richard McFetridge,Gretchen Tamms,Robert Lupinacci,Luwy Musey,Kara Bickham,on behalf of the V114-023 (PNEU-SICKLE) study group
View Articletitled, Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
Supplemental data

HEALTH SERVICES AND OUTCOMES

Neighborhood disadvantage, health status, and health care utilization after blood or marrow transplant: BMTSS report
Julie A. Wolfson,Smita Bhatia,Lindsey Hageman,E. S. Ross,Nora Balas,Alysia Bosworth,Hok Sreng Te,Liton Francisco,Erin Funk,Jessica Hicks,Wendy Landier,Jessica Wu,Arianna Siler,Shawn Lim,F. Lennie Wong,Saro H. Armenian,Mukta Arora,Monica S. Aswani
View Articletitled, Neighborhood disadvantage, health status, and health care utilization after blood or marrow transplant: BMTSS report
Supplemental data
Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance
Kate M. Johnson,Boshen Jiao,Scott D. Ramsey,M. A. Bender,Beth Devine,Anirban Basu
View Articletitled, Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies
Clinical Trials & Observations
Milos D. Miljkovic,Sigrid P. Dubois,Jürgen R. Müller,Bonita Bryant,Elaine Ma,Kevin C. Conlon,Thomas A. Waldmann
View Articletitled, Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52<sup>+</sup> T-cell malignancies
Supplemental data

LYMPHOID NEOPLASIA

Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment
Nicholas Borcherding,Kevin J. Severson,Nicholas Henderson,Luana S. Ortolan,Allison C. Rosenthal,Andrew M. Bellizzi,Vincent Liu,Brian K. Link,Aaron R. Mangold,Ali Jabbari
View Articletitled, Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment
Supplemental data
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia
Cory Seth Bridges,Taylor J. Chen,Monica Puppi,Karen R. Rabin,H. Daniel Lacorazza
View Articletitled, Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia
Supplemental data
Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations
Jingjing Ren,Rihao Qu,Nur-Taz Rahman,Julia M. Lewis,Amber Loren Ong King,Xiaofeng Liao,Fatima N. Mirza,Kacie R. Carlson,Yaqing Huang,Scott Gigante,Benjamin Evans,Barani Kumar Rajendran,Suzanne Xu,Guilin Wang,Francine M. Foss,William Damsky,Yuval Kluger,Smita Krishnaswamy,Michael Girardi
View Articletitled, Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations
Supplemental data

MYELOID NEOPLASIA

Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice
Andrew Muranyi,Tobias Ammer,Anna Kechter,Vijay P. S. Rawat,Amit Sinha,Irene Gonzalez-Menendez,Leticia Quintanilla-Martinez,Anca Azoitei,Cagatay Günes,Annalisa Mupo,George Vassiliou,Shiva Bamezai,Christian Buske
View Articletitled, Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice
Supplemental data
Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
Marius Bill,Madlen Jentzsch,Lara Bischof,Jessica Kohlschmidt,Juliane Grimm,Laura Katharina Schmalbrock,Donata Backhaus,Dominic Brauer,Karoline Goldmann,Georg-Nikolaus Franke,Vladan Vucinic,Dietger Niederwieser,Alice S. Mims,Uwe Platzbecker,Ann-Kathrin Eisfeld,Sebastian Schwind
View Articletitled, Impact of <em>IDH1</em> and <em>IDH2</em> mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
Supplemental data

PLATELETS AND THROMBOPOIESIS

Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
Aldo A. Acosta-Medina,Ann M. Moyer,Ronald S. Go,Maria Alice V. Willrich,Fernando C. Fervenza,Nelson Leung,Christianne Bourlon,Jeffrey L. Winters,Grant M. Spears,Sandra C. Bryant,Meera Sridharan,on behalf of the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group
View Articletitled, Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
Supplemental data

THROMBOSIS AND HEMOSTASIS

Differences in wild-type– and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies
Jonathan H. Foley,Erald Shehu,Anne Riddell,Elaine Gray,Andrew Goodale,I-Mei Yu,Daniël Verhoef,John Little,Diane Shattock,Steve Kitchen,Pratima Chowdary,Romuald Corbau,Amit C. Nathwani
View Articletitled, Differences in wild-type– and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies
Supplemental data

RESEARCH LETTERS

Persistence of chronic inflammation after regular blood transfusion therapy in sickle cell anemia
Clinical Trials & Observations
Abdoul Karim Dembélé,Patricia Hermand,Florence Missud,Emmanuelle Lesprit,Laurent Holvoet,Valentine Brousse,Ghislaine Ithier,Marie-Helene Odievre,Malika Benkerrou,Caroline Le Van Kim,Berengere Koehl
View Articletitled, Persistence of chronic inflammation after regular blood transfusion therapy in sickle cell anemia
Supplemental data
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas
Giovanni Rindone,Andrea Aroldi,Elisa Bossi,Luisa Verga,Giovanni Zambrotta,Sara Tarantino,Rocco Piazza,Lara Mussolin,Roberto Chiarle,Carlo Gambacorti-Passerini
View Articletitled, A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK<sup>+</sup> lymphomas
Supplemental data
CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
Clinical Trials & Observations
Khoan Vu,Matthew J. Frank
View Articletitled, CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM
Clinical Trials & Observations
Katharina Kriegsmann,Calin Manta,Ricarda Schwab,Elias K. Mai,Marc S. Raab,Hans J. Salwender,Roland Fenk,Britta Besemer,Jan Dürig,Roland Schroers,Ivana von Metzler,Mathias Hänel,Christoph Mann,Anne M. Asemissen,Bernhard Heilmeier,Uta Bertsch,Stefanie Huhn,Carsten Müller-Tidow,Hartmut Goldschmidt,Michael Hundemer
View Articletitled, Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM
Supplemental data
White blood cell ranges and frequency of neutropenia by Duffy genotype status
Clinical Trials & Observations
Minoo Bagheri,Cecilia P. Chung,Alyson L. Dickson,Sara L. Van Driest,Scott C. Borinstein,Jonathan D. Mosley
View Articletitled, White blood cell ranges and frequency of neutropenia by Duffy genotype status
Supplemental data
A novel, effective, and efficient strategy for treating sickle cell vaso-occlusive events in the infusion center setting
Clinical Trials & Observations
Scott A. Peslak,Alexis Brimm Akins,Anessa M. Foxwell,Marie Iannelli,Carolyn Grande,Delisha Breen,J. Eric Russell,Tanya J. Uritsky,Farzana A. Sayani
View Articletitled, A novel, effective, and efficient strategy for treating sickle cell vaso-occlusive events in the infusion center setting
Supplemental data

ERRATA

Cheng PTM, Villa D, Tonseth RP, et al. Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. Blood Adv. 2021;5(18):3647-3655.
View Articletitled, Cheng PTM, Villa D, Tonseth RP, et al. Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. <em>Blood Adv</em>. 2021;5(18):3647-3655.
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847.
View Articletitled, Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <em>KMT2A</em>-rearranged AML. <em>Blood Adv.</em> 2022;6(3):828-847.
All Issues

Advertisement

Steroid tapering after GVHD Rx: not too fast, not too slow
Better eat!
Survival for the fittest: guadecitabine in rel/ref AML
Sahin I, Kawano Y, Sklavenitis-Pistofidis R, et al. Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Adv. 2019;3(7):995-1002.
Jian Y, Chang L, Shi M-X, et al. Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment. Blood Adv. 2023;7(24):7581-7584.

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement